NEW PROTEIN MARKERS OF RENAL DAMAGE

Urine based diagnosis for non-invasive monitoring of renal fibrosis grade



OVERVIEW

Renal fibrosis is the major cause of chronic dysfunction and graft-loss in kidney transplant patients. The current "gold standard" for the diagnosis of chronic dysfunction is renal biopsy.

Chronic kidney disease (CKD) affects approximately 10% of the general population. While improving survival and quality of life, kidney-transplant patients **are susceptible to a host of complications, such as renal fibrosis.**

PROJECT

Sector: Nephrology

R&D direction:
Diagnosis and monitoring of renal fibrosis

Stage of development: TRL 3-4

Scientific leader: Dr. Francesc Borràs

Clinical Advisor: Dr. Ricardo Lauzurica

PRODUCT

Potential indications:
- ✓ Identification of fibrosis grade
- ✓ Monitorization of renal fibrosis

Mechanism of action:
Urinary biomarker test

Market size: 19.6M tests per year

Market value: €445M per year

IP PROTECTION

PCT Application

OPPORTUNITY

License out

Co-development

Spin-off generation

NEEDS

Renal biopsy is a highly invasive method, with risk for patients, of limited repeatability, with around 20% inaccurate diagnoses and a cost ranging from 500€ to 1000€ per procedure.

It is therefore necessary to find and develop **non-invasive strategies** to replace this procedure. The identification **of specific biomarkers** in the urinary exosomes can help replacing this technique by a less invasive diagnostic.

SOLUTION

- **Fibrokit**: A new non-invasive IVD test for continuous monitoring of kidney fibrosis.

This diagnostic kit is based on **urinary biomarkers** that positively correlate with the **degree of renal fibrosis** in kidney-transplant patients.

It is a non-invasive alternative to renal biopsy, to improve diagnosis and objectively monitoring renal fibrosis patients with CKD, including kidney-transplant patients.

KEY ADVANTATGES

- Easily accessible and non-invasive: from urine
- Repeatability: measurements can be repeated at clinical demand
- Cost-effective test: based on widely used laboratory techniques
- Improve patient monitorization with no risk, no contraindications and no disturbance
- Accurate evaluation: objective support in taking clinical decisions

CONTACT US!

innovation@igtp.cat

Innovation & Business Development Unit

IGTP
Germans Trias i Pujol Research Institute